{"id":"NCT00250276","sponsor":"GlaxoSmithKline","briefTitle":"Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.","officialTitle":"Assess Lot-to-lot Consistency of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Following Manufacturing Adjustments Administered Intramuscularly According to a 0,1,6-mth Schedule in Healthy Female Subjects (18-25 y)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10-28","primaryCompletion":"2007-03-01","completion":"2007-03-01","firstPosted":"2005-11-08","resultsPosted":"2017-03-17","lastUpdate":"2020-01-02"},"enrollment":798,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Papillomavirus","Papillomavirus Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"Cervarixâ„¢","otherNames":[]}],"arms":[{"label":"Cervarix Lot1 Group","type":"EXPERIMENTAL"},{"label":"Cervarix Lot2 Group","type":"EXPERIMENTAL"},{"label":"Cervarix Lot3 Group","type":"EXPERIMENTAL"},{"label":"Cervarix Low Group","type":"EXPERIMENTAL"}],"summary":"Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. Indeed, the infection of the cervix by certain oncogenic types of HPV, if not cleared , can lead over time to cervical cancer in women . This study will compare the immune response induced by different lots of the HPV-16/18 L1/AS04 vaccine, following adjustments to the manufacturing process.","primaryOutcome":{"measure":"Number of Seroconverted (SCR) Subjects for Anti-Human Papillomavirus Type 16 (Anti-HPV-16) and Anti-Human Papillomavirus Type 18 (Anti-HPV-18)","timeFrame":"At Month 7","effectByArm":[{"arm":"Cervarix Lot1 Group","deltaMin":118,"sd":null},{"arm":"Cervarix Lot2 Group","deltaMin":127,"sd":null},{"arm":"Cervarix Lot3 Group","deltaMin":126,"sd":null},{"arm":"Pooled Group","deltaMin":371,"sd":null},{"arm":"Cervarix Low Group","deltaMin":102,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG003 vs OG004","p":null},{"comp":"OG003 vs OG004","p":null},{"comp":"OG003 vs OG004","p":null},{"comp":"OG003 vs OG004","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":8,"countries":["Denmark","Lithuania","Poland"]},"refs":{"pmids":["19221517"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":199},"commonTop":["Pain","Redness","Swelling","Fatigue","Headache"]}}